Marina Ramirez-Alvarado

Marina Ramirez-Alvarado

Auto-generated profile, based on publicly available information

Marina Ramirez-Alvarado

Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, USA

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2017 in Amyloid
Verified
Journal Article
Closed access
KMKirsten Gade Malmos
Kirsten Gade Malmos
LBLuis M. Blancas-Mejia
Luis M. Blancas-Mejia
BWBenedikt Weber
Benedikt Weber
JBJohannes Buchner
Johannes Buchner
MRMarina Ramirez-Alvarado
Marina Ramirez-Alvarado
DODaniel Otzen
Daniel Otzen
Thioflavin T (ThT) has been widely used to investigate amyloid formation since 1989. While concerns have recently been raised about its use as a probe specific for amyloid, ThT still continues to be a very valuable tool for studying kinetic aspects of fibrillation and associated inhibition mechanisms. This review aims to provide a conceptual instruction manual, covering appropriate considerations and pitfalls related to the use of ThT. We start by giving a brief introduction to amyloid formation with focus on the morphology of different aggregate species, followed by a discussion of the quality of protein needed to obtain reliable fibrillation data. After an overview of the photochemical basis for ThT’s amyloid binding properties and artifacts that may arise from this, we describe how to plan and analyze ThT assays. We conclude with recommendations for complementary techniques to address shortcomings in the ThT assay.

10 July 1998 in Science
Verified
Journal Article
Closed access
PDF file
TKTanja Kortemme
Tanja Kortemme
MRMarina Ramı́rez-Alvarado
Marina Ramı́rez-Alvarado
LSLuis Serrano
Luis Serrano
A 20-residue protein (named Betanova) forming a monomeric, three-stranded, antiparallel β sheet was designed using a structural backbone template and an iterative hierarchical approach. Structural and physicochemical characterization show that the β-sheet conformation is stabilized by specific tertiary interactions and that the protein exhibits a cooperative two-state folding-unfolding transition, which is a hallmark of natural proteins. The Betanova molecule constitutes a tractable model system to aid in the understanding of β-sheet formation, including β-sheet aggregation and amyloid fibril formation.

1 August 2003 in Biophysical Journal
Verified
Journal Article
Closed access
RKRitu Khurana
Ritu Khurana
CICristian Ionescu-Zanetti
Cristian Ionescu-Zanetti
MPMaighdlin Pope
Maighdlin Pope
JLJie Li
Jie Li
LNLiza Nielson
Liza Nielson
SCSue A. Carter
Sue A. Carter

2 June 2013 in Annual Review of Biochemistry
Verified
Journal Article
Closed access
LBLuis M. Blancas-Mejía
Luis M. Blancas-Mejía
MRMarina Ramirez-Alvarado
Marina Ramirez-Alvarado
The amyloidoses are a group of protein misfolding diseases in which the precursor protein undergoes a conformational change that triggers the formation of amyloid fibrils in different tissues and organs, causing cell death and organ failure. Amyloidoses can be either localized or systemic. In localized amyloidosis, amyloid deposits form at the site of precursor protein synthesis, whereas in systemic amyloidosis, amyloid deposition occurs distant from the site of precursor protein secretion. We review the type of proteins and cells involved and what is known about the complex pathophysiology of these diseases. We focus on light chain amyloidosis to illustrate how biochemical and biophysical studies have led to a deeper understanding of the pathogenesis of this devastating disease. We also review current cellular, tissue, and animal models and discuss the challenges and opportunities for future studies of the systemic amyloidoses.

25 July 2000 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
MRMarina Ramírez-Alvarado
Marina Ramírez-Alvarado
JMJane S. Merkel
Jane S. Merkel
LRLynne Regan
Lynne Regan
There are a number of diseases in which normally soluble proteins associate into regular, insoluble amyloid fibrils. The development of in vitro model systems in which detailed structural, kinetic, and thermodynamic characterization are feasible is of critical importance to our understanding of the amyloid fibril phenomenon. The formation of amyloid fibrils by proteins that are not associated with disease has been recently described, suggesting that this may be a common property of many proteins and not only of the few proteins associated with amyloidoses. The B1 Ig-binding domain of protein G (β1) is an extremely well-characterized model system. We have found that under certain experimental conditions, some variants of β1 form fibrils with high reproducibility. By controlling the stability of the protein—either by mutations or by changing experimental conditions—we are able to modulate the ability of the protein to form fibrils. For all of the variants, we find that the key requirement for fibril formation is to choose conditions in which the population of intermediate conformations present during the unfolding transition is maximized.

9 December 2010 in Blood
Verified
Journal Article
Open access
PDF file
SKShaji Kumar
Shaji Kumar
ADAngela Dispenzieri
Angela Dispenzieri
JKJerry A. Katzmann
Jerry A. Katzmann
DLDirk R. Larson
Dirk R. Larson
CCColin L. Colby
Colin L. Colby
MGMorie A. Gertz
Morie A. Gertz
Immunoglobulin free light chains (FLCs) are the precursors of amyloid fibrils in primary amyloidosis (AL). We studied the relationship between FLC levels and clinical features in 730 patients with newly diagnosed AL. The plasma cell clone was λ in 72% patients, and κ in 28% patients. κ-AL had more GI tract and liver involvement, where as renal involvement was more with λ-AL. While the overall survival (OS) was similar for κ and λ-AL, the median OS for those without an identifiable serum heavy chain was significantly shorter (12.6 vs 29.9 months; P = .02). The OS was shorter among those with a higher dFLC (involved FLC−uninvolved FLC; κ > 29.4 mg/dL or λ > 18.2 mg/dL using median for cutoff); 10.9 vs 37.1 months; P < .001. In multivariate analysis, dFLC was independent of other prognostic factors. The type of light chain impacts the spectrum of organ involvement and the FLC burden correlates with survival in AL.